> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 8 Items on Aurobindo FDA-483
- URL: https://www.fdaweb.com/8-items-on-aurobindo-fda-483/
- Published: 2025-10-09T12:00:00.000Z
- Updated: 2026-09-14T15:23:46.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160016

FDA has released the form FDA-483 with eight observations from an 8/25-9/5 inspection at the Aurobindo Pharma drug manufacturing facility in Bachupally, Hyderabad, India. The inspection observations were:

- procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed, or the procedures did not include adequate validation of the aseptic process;
- aseptic processing areas are deficient regarding the system for monitoring environmental conditions;
- failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed;
- failure to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess;
- failure to follow written production and process control procedures in the execution of production and process control functions, and documented at the time of performance;
- failure to clean at appropriate intervals equipment and utensils to prevent contamination that would alter the safety, identity, strength, quality, or purity of the drug product;
- failure to maintain in a good state of repair buildings used in the manufacturing, processing, packing, and holding of a drug product; and
- failure to fully follow the responsibilities and procedures applicable to the quality control unit.